Integrated Filing — IndAS



General information about company
Scrip Code 544172
NSE Symbol INDGN
MSEI Symbol NOTLISTED
ISIN INE065X01017
Name of company Indegene Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 31-Jul-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 24-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 31-Jul-2025   16:40:00
End date and time of board meeting 31-Jul-2025   16:58:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 7608000000
Other income 221000000
Total income 7829000000
2 Expenses
(a) Cost of materials consumed 0
(b) Purchases of stock-in-trade 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0
(d) Employee benefit expense 4815000000
(e) Finance costs 37000000
(f) Depreciation, depletion and amortisation expense 216000000
(f) Other Expenses
1 Other expenses 1240000000 1240000000
Total other expenses 1240000000
Total expenses 6308000000
3 Total profit before exceptional items and tax 1521000000
4 Exceptional items 0
5 Total profit before tax 1521000000
6 Tax expense
7 Current tax 284000000
8 Deferred tax 73000000
9 Total tax expenses 357000000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 1164000000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period 1164000000
17 Other comprehensive income net of taxes 167000000
18 Total Comprehensive Income for the period 1331000000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 1164000000
Total profit or loss, attributable to non-controlling interests 0
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 167000000
Total comprehensive income for the period attributable to owners of parent non-controlling interests 1331000000
21 Details of equity share capital
Paid-up equity share capital 479000000
Face value of equity share capital 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.86
Diluted earnings (loss) per share from continuing operations 4.82
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.86
Diluted earnings (loss) per share from continuing and discontinued operations 4.82
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) Earnings per share is not annualised for quarter ended n nNotes to the Statement of Consolidated Financial Results for the quarter ended 30 June 2025 nAll amounts in INR millions except share data and where otherwise stated n1 The above Consolidated Financial Results of Indegene Limited the Company or the Parent or the Holding Company together with its affiliates collectively the Group have been prepared in accordance with Indian Accounting Standards Ind AS 34 Interim Financial Reporting recognition and measurement principles of Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act 2013 as amended read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 the Regulations Due to rounding off the numbers presented throughout may not add up precisely to the totals The symbol caret in the financial information denote amounts less than INR 5 lakhs n2 The above consolidated results have been reviewed by the Audit Committee meeting held on 29 July 2025 and approved by the Board of Directors at its meeting held on 31 July 2025 The statutory auditors have performed a limited review of the Consolidated Financial Results for the quarter ended 30 June 2025 and have issued an unmodified review report on the same n3 The Consolidated Financial Results include the results for the quarter ended 31 March 2025 being the balancing figures between audited figures in respect of the full financial year up to 31 March 2025 and the unaudited published year to date figures up to 31 December 2024 being the date of the end of the third quarter of the financial year which were subjected to a limited review n4 The Consolidated Financial Results for the quarter ended 30 June 2025 are available on the National Stock Exchange of India Limited URL www nseindia com the BSE Limited website URL www bseindia com and on the Company s website URL www indegene com investorrelations n5 Acquisition of MJL Communications Group Ltd n On 25 March 2025 the Group had obtained control of MJL Communications Group Ltd MJL by acquiring 100 percent of its shares The acquisition was consummated for a consideration of INR 411 which includes earnout payment of INR 150 The contingent consideration is based on the performance of MJL during the fiscal year beginning 01 April 2025 and ending 31 March 2027 and range of contingent consideration payable is between Nil to INR 172 The Group has concluded that the acquisition is a Business nThe fair value of net assets acquired on the acquisition date as a part of the transaction amounted to INR 98 The excess of purchase consideration over the fair value of net assets acquired has been attributed towards the identifiable intangible assets aggregating to INR 174 and goodwill aggregating to INR 139



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Enterprise Medical Solutions 2132000000 2132000000
2 Enterprise Commercial Solutions 4453000000 4453000000
3 Brand Activation 758000000 758000000
4 Others 265000000 265000000
Total Segment Revenue 7608000000
Less: Inter segment revenue 0 0
Revenue from operations 7608000000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Enterprise Medical Solutions 576000000 576000000
2 Enterprise Commercial Solutions 1048000000 1048000000
3 Brand Activation 51000000 51000000
4 Others -50000000 -50000000
Total Profit before tax 1625000000
i. Finance cost 37000000 37000000
ii. Other Unallocable Expenditure net off Unallocable income 67000000 67000000
Profit before tax 1521000000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Enterprise Medical Solutions 0 0
2 Enterprise Commercial Solutions 0 0
3 Brand Activation 0 0
4 Others 0 0
Total Segment Asset 0 0
Un-allocable Assets 0 0
Net Segment Asset 0 0
4 Segment Liabilities
Segment Liabilities
1 Enterprise Medical Solutions 0 0
2 Enterprise Commercial Solutions 0 0
3 Brand Activation 0 0
4 Others 0 0
Total Segment Liabilities 0 0
Un-allocable Liabilities 0 0
Net Segment Liabilities 0 0
Disclosure of notes on segments Textual Information(2)



Text Block
Textual Information(2) 6 The Segment results of the Group has been prepared in accordance with Ind AS 108 on Operating Segments The Group has identified business segments industry practice as reportable segments The reportable business segments comprise 1 Enterprise Medical Solutions 2 Enterprise Commercial Solutions 3 Brand Activation n nEffective 1 April 2025 the Omnichannel Activation segment has been renames as Brand Activation nOthers mainly comprises of consultancy and clinical business n nNotes on Segment information nOperating segments are identified as components of an enterprise for which discrete financials information is available that is evaluated regularly by the chief operating decision maker In deciding how to allocate resources and assessing performance the Group s chief operating decision maker is the Chief Executive Officer and Executive Director nAssets and liabilities used in the Group s business are not identified to any of the operating segments as these are used interchangeably between segments Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous n n7 Final dividend for the Financial Year 2024 25 of INR 2 per share was approved by the shareholders at the 27th Annual General Meeting held on 26 June 2025 and the same was paid on 30 June 2025 n nOther unallocable expenditure net of unallocable income for the three months ended 30 Jun 2025 includes depreciation and amortisation expense INR 216 and unallocable expenses INR 72 net of other income INR 221



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit obligation 12000000 12000000
Total Amount of items that will not be reclassified to profit and loss 12000000
2 Income tax relating to items that will not be reclassified to profit or loss 3000000
3 Amount of items that will be reclassified to profit and loss
1 Exchange differences on translating the financial statements of foreign operations 158000000 158000000
Total Amount of items that will be reclassified to profit and loss 158000000
4 Income tax relating to items that will be reclassified to profit or loss 0
5 Total Other comprehensive income 167000000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deloitte Haskins & Sells Yes 30-Apr-2028